Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients

Oncoimmunology. 2023 Sep 14;12(1):2253644. doi: 10.1080/2162402X.2023.2253644. eCollection 2023.

Abstract

Cancer cells favor the generation of myeloid cells with immunosuppressive and inflammatory features, including myeloid-derived suppressor cells (MDSCs), which support tumor progression. The anti-apoptotic molecule, cellular FLICE (FADD-like interleukin-1β-converting enzyme)-inhibitory protein (c-FLIP), which acts as an important modulator of caspase-8, is required for the development and function of monocytic (M)-MDSCs. Here, we assessed the effect of immune checkpoint inhibitor (ICI) therapy on systemic immunological landscape, including FLIP-expressing MDSCs, in non-small cell lung cancer (NSCLC) patients. Longitudinal changes in peripheral immunological parameters were correlated with patients' outcome. In detail, 34 NSCLC patients were enrolled and classified as progressors (P) or non-progressors (NP), according to the RECIST evaluation. We demonstrated a reduction in pro-inflammatory cytokines such as IL-8, IL-6, and IL-1β in only NP patients after ICI treatment. Moreover, using t-distributed stochastic neighbor embedding (t-SNE) and cluster analysis, we characterized in NP patients a significant increase in the amount of lymphocytes and a slight contraction of myeloid cells such as neutrophils and monocytes. Despite this moderate ICI-associated alteration in myeloid cells, we identified a distinctive reduction of c-FLIP expression in M-MDSCs from NP patients concurrently with the first clinical evaluation (T1), even though NP and P patients showed the same level of expression at baseline (T0). In agreement with the c-FLIP expression, monocytes isolated from both P and NP patients displayed similar immunosuppressive functions at T0; however, this pro-tumor activity was negatively influenced at T1 in the NP patient cohort exclusively. Hence, ICI therapy can mitigate systemic inflammation and impair MDSC-dependent immunosuppression.

Keywords: ICI (immune checkpoint inhibitor); M-MDSCs (monocytic myeloid-derived suppressor cells), c-FLIP (cellular FLICE [FADD-like IL-1β-converting enzyme]- inhibitory protein); NSCLC (non-small cell lung cancer).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immune Checkpoint Inhibitors / therapeutic use
  • Lung Neoplasms* / drug therapy
  • Monocytes
  • Myeloid-Derived Suppressor Cells*

Substances

  • Immune Checkpoint Inhibitors

Grants and funding

This work was jointly supported by both Stefano Ugel grants of the Fondazione Italiana per la Ricerca sul Cancro (AIRC) (MFAG project: 21509), PRIN program of Italian Ministry of University and Research (MUR, CUP: B38D19000140006), Fondazione Cariverona (ENACT project) and PNRR programs of the Italian MUR (Project “National Center for Gene Therapy and Drugs based on RNA Technology”, application code CN00000041, Mission 4, Component 2 Investment 1.4, funded from the European Union – NextGeneration EU, MUR Directorial Decree No. 1035 of 17 June 2022, CUP B33C22000630001); Vincenzo Bronte grants funded by Fondazione Cariverona (project call, 2017), Fondazione AIRC (IG project: 23788), Cancer Research Institute (Clinic and Laboratory Integration Program, CLIP 2020), and PRIN program of Italian MUR (CUP: B38D19000260006). Annalisa Adamo was supported by AIRC/FIRC fellowship call 2019; Chiara Musiu was supported by AIRC fellowship call 2022. Emilio Bria. is supported by Fondazione AIRC (IG project: 20583) and by Institutional funds of Università Cattolica del Sacro Cuore (UCSC-project D1). Carmine Carbone is supported by Fondazione AIRC (MFAG project: 23681). Francesco De Sanctis is supported by the PRIN program of Italian MUR (CUP: B39J22001200001). Fang Qi is sponsored by the China scholarship Council (No. 202108520059) at the University of Verona.